Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05790681 · ClinicalTrials.gov registry record · Phase 1
A Study to Test How New Long-acting Insulin (Insulin Icodec) Works in the Body of Children and Teenagers
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT05790681 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 18 participants.
The verdict
NCT05790681, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
Insulin icodec is a new medicine which is under development for use in humans and is not yet available at the pharmacy. It is being developed for the treatment of diabetes, a condition that causes high blood sugar levels. Insulin icodec will be investigated in participants with type 2 diabetes. Participant will get one dose of insulin icodec, which will be administered in the afternoon or evening of the day of dosing. The study will last for about 8 weeks. Insulin icodec will be injected into a skin fold with a small needle (subcutaneous application) using a pen injector prefilled with a volume of 3 milliliter (mL) (a little less than a quarter of a teaspoonful). The amount of insulin icodec participant will receive depends on participant's body weight. Participant must not participate if participant meets certain conditions called exclusion criteria, such as an age of above 18 years when the informed consent is signed or has serious health conditions. Female participant cannot take part if she is pregnant, breast-feeding or planning to become pregnant during the study period.
Interventions
- DRUG Insulin icodec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2023-04-25 |
| Est. Completion | 2024-02-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05790681
The ClinicalTrials.gov registry entry for NCT05790681 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Insulin icodec is the first listed.
NCT05790681 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05790681 about?
NCT05790681 is a clinical study titled "A Study to Test How New Long-acting Insulin (Insulin Icodec) Works in the Body of Children and Teenagers". Insulin icodec is a new medicine which is under development for use in humans and is not yet available at the pharmacy. It is being developed for the treatment of diabetes, a condition that causes high blood sugar levels. Insulin icodec will be investigated in participants with type 2 diabetes. Part...
What is the current status of trial NCT05790681?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2023-04-25. Estimated completion is 2024-02-08.
What interventions are being tested in trial NCT05790681?
The interventions under investigation include: Insulin icodec (DRUG).
Who is sponsoring clinical trial NCT05790681?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.